Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility

Executive Summary

Changes to FDA's interpretation of the GRASE standard it uses to evaluate ingredient proposals would go further to opening the US monograph process to innovation and progress than setting deadlines for the reviews, industry stakeholders say.

Advertisement

Related Content

OTC Monograph Reform Proposal Offers Two-Tier Approach
Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA
Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA
FDA Sunscreen Guidance: Absorption Data Is A MUsT For GRASE Review
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
FDA Proposes Illuminating OTC Monograph Process With Sunscreen TEA Framework
OTC Regulatory Pathway Needs NDA Flexibility, Monograph Scope – Sharfstein
“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock

Topics

Advertisement
UsernamePublicRestriction

Register

PS119592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel